Staphylococcus aureus and the Skin Microbiome

What is Staphylococcus aureus and where does it live on skin?

Staphylococcus aureus (often called S. aureus or staph) is a spherical bacterium that can live harmlessly on skin or cause infections ranging from minor boils to life-threatening disease. Unlike its close relative Staphylococcus epidermidis, which peacefully inhabits nearly everyone's skin, S. aureus colonizes the nostrils and skin of roughly 20–30% of healthy adults intermittently or persistently. When skin is intact and the microbiome is balanced, S. aureus typically remains in check at low abundance or absent altogether.

The distinction between colonization and infection depends heavily on context: barrier integrity, immune status, and competition from other microbes. In healthy skin, resident bacteria like S. epidermidis and Cutibacterium acnes occupy ecological niches and produce antimicrobial peptides that limit S. aureus expansion. When these defenses falter—through cuts, eczema, or antibiotic disruption—S. aureus can proliferate and invade deeper tissue.

How does S. aureus shift from colonizer to pathogen?

The transition from harmless carriage to disease involves a combination of bacterial virulence factors and host vulnerability. S. aureus produces an arsenal of toxins, proteases, and adhesion molecules that degrade skin proteins, evade immune cells, and form protective biofilms. Alpha-toxin, for instance, punches holes in keratinocytes and immune cells, while staphylococcal enterotoxins act as superantigens that trigger overwhelming inflammation.

Skin barrier disruption is a critical trigger. In conditions like atopic dermatitis, mutations in the filaggrin gene impair the stratum corneum's structure, creating cracks that allow S. aureus to adhere and penetrate. The bacterium then releases proteases that further degrade tight junction proteins and antimicrobial peptides, creating a vicious cycle of barrier breakdown and microbial invasion.

Microbiome imbalance amplifies the problem. Studies show that S. aureus can outcompete beneficial commensals when microbial diversity drops, particularly after aggressive cleansing or antibiotic use. The loss of S. epidermidis, which produces serine proteases and antimicrobial peptides that specifically inhibit S. aureus, removes a key ecological brake on pathogen expansion.

What role does S. aureus play in eczema and atopic dermatitis?

Staphylococcus aureus dominates the skin microbiome during atopic dermatitis flares, often comprising over 90% of the bacterial population in lesional skin. This near-monoculture is both a cause and consequence of disease: the bacterium worsens inflammation, and inflammation creates conditions that favor S. aureus growth. Landmark metagenomic studies by Kong, Segre, and colleagues demonstrated that microbial diversity plummets during flares while S. aureus abundance skyrockets, then partially rebounds during treatment and healing.

The bacterium exacerbates eczema through multiple mechanisms. Delta-toxin and phenol-soluble modulins directly damage keratinocytes and trigger mast cell degranulation, intensifying itch and inflammation. Protein A on the bacterial surface binds antibodies in an immune-evading orientation while simultaneously activating inflammatory pathways. Staphylococcal superantigens bypass normal immune regulation, causing massive T-cell activation and cytokine release that perpetuates the Th2-skewed inflammation characteristic of atopic dermatitis.

Colonization density correlates with disease severity. Children with moderate-to-severe eczema carry higher S. aureus loads than those with mild disease, and targeted reduction of S. aureus—through dilute bleach baths or topical antimicrobials—often improves symptoms. This observation has fueled interest in microbiome-targeted therapies that restore competitive commensals rather than simply sterilizing the skin.

Can beneficial bacteria protect against S. aureus?

Commensal staphylococci, particularly Staphylococcus epidermidis, produce antimicrobial compounds that specifically inhibit S. aureus colonization and virulence. Studies from the Gallo laboratory demonstrated that certain S. epidermidis strains secrete serine protease Esp, which degrades S. aureus biofilms and neutralizes its toxins. Additionally, S. epidermidis produces lantibiotics (bacteriocins with modified amino acids) that kill S. aureus by disrupting its cell membrane.

Coagulase-negative staphylococci also modulate the immune system in ways that indirectly suppress S. aureus. S. epidermidis lipoteichoic acid stimulates keratinocytes to produce antimicrobial peptides like beta-defensins and cathelicidin, fortifying the skin's chemical barrier. In mouse models, animals pre-colonized with commensal staphylococci showed enhanced resistance to S. aureus skin infection compared to germ-free controls.

Clinical trials are testing whether transplanting beneficial S. epidermidis or Roseomonas mucosa strains onto eczema-prone skin can durably suppress S. aureus and reduce flares. Early-phase results suggest that autologous transplantation (using a patient's own commensal strains from healthy skin sites) can reduce S. aureus burden and improve symptoms, though larger studies are needed to confirm efficacy and safety.

How do skin care practices influence S. aureus colonization?

Harsh cleansing and broad-spectrum antimicrobials can paradoxically increase S. aureus risk by eliminating competitive commensals. While short-term antimicrobial interventions reduce colonization during active infection, prolonged or indiscriminate use disrupts microbial diversity and may select for resistant strains. The soap surfactants that strip lipids also remove antimicrobial fatty acids and damage the acid mantle (pH 4.5–5.5) that naturally inhibits S. aureus growth.

Moisturization and barrier repair support a balanced microbiome. Emollients containing ceramides, cholesterol, and free fatty acids restore stratum corneum integrity, reducing the micro-fissures that allow S. aureus adherence. Some studies suggest that earlier, more aggressive emollient use in infants at high eczema risk may prevent the initial S. aureus colonization that kickstarts the atopic march, though results remain mixed.

Targeted antimicrobial strategies—dilute sodium hypochlorite baths, topical antimicrobial peptides, or selective bacteriophages—aim to reduce S. aureus without collateral damage to the broader microbiome. These approaches remain under investigation but represent a more ecologically nuanced alternative to traditional antibiotics.

The bottom line

Staphylococcus aureus occupies a precarious position in the skin microbiome: a potential pathogen held in check by an intact barrier and diverse microbial community. When that balance is disturbed—through barrier disruption, antibiotic overuse, or immune dysregulation—S. aureus can rapidly expand, driving cycles of inflammation and infection. Managing colonization effectively may therefore require restoring the ecological conditions that keep it in check: barrier repair, microbiome diversity, and targeted rather than broad-spectrum antimicrobial strategies.